Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vikki Keersmaekers

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
BMC Bioinformatics|July 10, 2019
Analyzing magnetic bead QuantiGene® Plex 2.0 gene expression data in high throughput mode using QGprofilerBie Verbist, Eva Adriaensen, Vikki Keersmaekers, et al.
Molecular Cancer Therapeutics|September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor ActivityDirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
BMC Bioinformatics|July 10, 2019
Analyzing magnetic bead QuantiGene® Plex 2.0 gene expression data in high throughput mode using QGprofilerBie Verbist, Eva Adriaensen, Vikki Keersmaekers, et al.
Molecular Cancer Therapeutics|September 29, 2021
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor ActivityDirk Brehmer, Lijs Beke, Tongfei Wu, et al.
Blood|June 21, 2024
Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasMin Chul Kwon, Jan Willem Thuring, Olivier Querolle, et al.
Pageof 1